

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Hotchkiss RS, Opal SM. Activating immunity to fight a foe — a new path. *N Engl J Med* 2020; 382:1270-2. DOI: 10.1056/NEJMcibr1917242

## REFERENCES FOR IMMUNOTHERAPY (IL-7, $\alpha$ PD-1, $\alpha$ PD-L1, GM-CSF, IFN- $\gamma$ ) USE IN CLINICAL (HUMAN) INFECTIONS

### Viral

#### IL-7

1. Harel A, Horng S, Gustafson T, Ramineni A, Farber RS, Fabian M. Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia. *J Neurovirol* 2018;24:652-5.
2. Alstadhaug KB, Croughs T, Henriksen S, et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. *JAMA Neurol* 2014;71:1030-5.
3. Patel A, Patel J, Ikwuagwu J. A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. *J Antimicrob Chemother* 2010;65:2697-8.
4. Miskin DP, Chalkias SG, Dang X, Bord E, Batson S, Korolnik IJ. Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia. *Neurol Neuroimmunol Neuroinflamm* 2016;3:e213.
5. Gasnault J, de Goer de Herve MG, Michot JM, et al. Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. *Open Forum Infect Dis* 2014;1:ofu074.

#### $\alpha$ PD-1/ $\alpha$ PD-L1

6. Rauer S, Marks R, Urbach H, et al. Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab. *N Engl J Med* 2019;380:1676-7.
7. Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. *N Engl J Med* 2019;380:1597-605.
8. Korolnik IJ. Can Immune Checkpoint Inhibitors Keep JC Virus in Check? *N Engl J Med* 2019;380:1667-8.
9. Gardiner D, Lalezari J, Lawitz E, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. *PLoS One* 2013;8:e63818. (Clinical Trial)
10. Fuller MJ, Callendret B, Zhu B, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). *Proc Natl Acad Sci U S A* 2013;110:15001-6.
11. Walter O, Treiner E, Bonneville F, et al. Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab. *N Engl J Med* 2019;380:1674-6.

### Bacterial

#### IL-7

12. Francois B, Jeannot R, Daix T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. *JCI Insight* 2018;3. (Clinical Trial)

## □PD-1/□PD-L1

13. Hotchkiss RS, Colston E, Yende S, et al.: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559). *Crit Care Med.* 2019 May; 47(5):632-642.
14. Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. *Intensive Care Med.* 2019 Oct;45(10):1360-1371.

## GM-CSF

15. Hall MW, Geyer SM, Guo CY, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. *Crit Care Med* 2013;41:224-36. (Clinical Trial)
16. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. *Am J Respir Crit Care Med* 2009;180:640-8. (Clinical Trial)
17. Leentjens J, Kox M, Koch RM, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. *Am J Respir Crit Care Med* 2012;186:838-45. (Clinical Trial)

## IFN- $\gamma$

18. Riddell LA, Pinching AJ, Hill S, et al. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. *AIDS Res Hum Retroviruses* 2001;17:789-97. (Clinical Trial)
19. Nalos M, Santner-Nanan B, Parnell G, Tang B, McLean AS, Nanan R. Immune effects of interferon gamma in persistent staphylococcal sepsis. *Am J Respir Crit Care Med* 2012;185:110-2.
20. Payen D, Faivre V, Miatello J, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. *BMC Infect Dis* 2019;19:931.
21. Crit Care Med Payen D, Faivre V, Miatello J, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. *BMC Infect Dis* 2019;19:931.
22. Dries DJ, Jurkovich GJ, Maier RV, et al. Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. *Arch Surg* 1994;129:1031-41; discussion 42. (Clinical Trial)
23. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. *Nat Med* 1997;3:678-81.

## **Fungal**

### **$\alpha$ PD-1/IFN- $\gamma$**

24. Grimaldi D, Pradier O, Hotchkiss RS, Vincent JL. Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis. *Lancet Infect Dis* 2017;17:18.

### **GM-CSF**

25. Wan L, Zhang Y, Lai Y, et al. Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial. *J Clin Oncol* 2015;33:3999-4006. (**Clinical Trial**)

### **IFN- $\gamma$**

26. Delsing CE, Gresnigt MS, Leentjens J, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. *BMC Infect Dis* 2014;14:166.
27. Buddingh EP, Leentjens J, van der Lugt J, et al. Interferon-gamma Immunotherapy in a Patient With Refractory Disseminated Candidiasis. *Pediatr Infect Dis J* 2015;34:1391-4.